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Summary
Transformation of hematopoietic cells by the p210bcrlab' tyrosine kinase appears to require the
expression of a functional MYC protein, suggesting that simultaneous targeting of BCR-ABL
and c-myc might be a rational strategy for attempting treatment of Phil-adelphial leukemia. To
test this hypothesis, severe combined immunodeficiency mice injected with Philadelphia' leu-
kemic cells were treated systemically with equal doses ofbcr-abl or c-myc antisense oligodeox-
ynucleotides (ODNs) or with both ODNs in combination. Compared with the mice treated
with individual agents, the disease process was much slower in the group treated with both
ODNs, as revealed by flow cytometry, clonogenic assay, and reverse transcriptase-polymerase
chain reaction analysis to detect leukemic cells in mouse tissue cell suspensions, and by enu-
meration of liver metastases. The retardation of the disease process was positively correlated
with a markedly increased survival of leukemic mice treated with both ODNs . These data
demonstrate the therapeutic potential of targeting multiple cooperating oncogenes.
rowing evidence suggests that cancer arises through a
multistep process that involves activation of proto-
oncogenes and loss of function of tumor suppressor genes
(1, 2) . Oncogene cooperation was originally demonstrated
in vitro (3-5) and subsequently validated in vivo using
transgenic mouse models (6). Chronic myelogenous leuke-
mia (CML)' illustrates well the concept of a multistep pro-
cess in human malignancies, because the clinical course
consists of two well-defined stages, i.e., a relatively indo-
lent and long-lasting chronic phase and a terminal, more
aggressive blast crisis (7) . At the genetic level, the predomi-
nant abnormality of the chronic phase is the Philadelphia
chromosome (Ph') translocation, resulting in the formation
of the BCR-ABL oncogene . BCR-ABL expression deter-
mines the growth advantage ofPhiladelphia' cellsin part by
protecting them from apoptosis (8-10) . In blast crisis, sev-
eral other abnormalities might be present, including inacti-
vation ofthe p53 tumor suppressor gene, chromosomal tri-
somy, and additional translocations (11-13). Several lines of
evidence also suggest that MYC cooperates with and is re-
'Abbreviations used in this paper: AS, antisense; BMC, bone marrow cell;
CML, chronic myelogenous leukemia; ODN, oligodeoxynucleotide;
PBL, peripheral blood leukocyte; Ph', Philadelphia chromosome; Qt/
RT-PCR, quantitative PT-PCR; RT, reverse transcriptase; S, sense;
[S]ODN, phosphorothioate ODN; SPL, spleen; TBS, Tris-buffered
saline.
quired for BCR-ABL or v-ABL transformation of he-
matopoietic and nonhematopoietic cells (14-18) . Thus, to
test whether simultaneous targeting ofBCR-ABL (the ini-
tiating agent of the disease process) and c-myc (a transcrip-
tional end point of BCR-ABL-mediated events) in CML
cells represents a novel and effective modality of leukemia
treatment, we compared the effects of phosphorothioate
bcr-abl and c-myc antisense (AS) oligodeoxynucleotides
(ODNs) alone and in combination in vitro and on leuke-
mia development in immunodeficient (SCID) mice.
Materials and Methods
Mice and Leukemia Cells.
￿
Outbred ICR-SCID male mice (7-9
wk old from Taconic Farms, Inc., Germantown, NY) and BV173
leukemic cells were used as previously described (19) . According
to testing performed by the vendor, the frequency of "leaky"
SCID mice in the population is <1%.
ODNs .
￿
ODNs were prepared on an automated synthesizer
(model 390Z; Applied Biosystems, Foster City, CA) . The bcr-abl
(26-mer, b2/a2) and c-myc (26-mer from the initiation codon)
sense (S) and AS phosphorothioate ODNs ([S]ODNs) were de-
scribed previously (19, 20). Sequences of the 3' primer of ABL
exon 2 3' primer of [3-actin, 5' primers of BCR exon 2 and 5'
primer of [3-actin, and the ABL and [3-actin probes recognizing
amplified transcripts have been published (21, 22).
(SJODNs Treatment ofBV173 Cells In Vitro.
￿
BV173 cells (104/
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RPMI 1640 medium supplemented with 10%fetal bovine serum,
L-glutamine, and penicillin/streptomycin. For protein studies and
cell cycle analysis, 5 X 106 BV173 cells/20 ml of medium were
placed in a 175-cm2 tissue culture flask (LUX; Nunc, Inc., Na-
perville, IL). S or AS [S]ODNs were added at the beginning of
culture and again (at 50% of the initial dose) 24 and 48 h later.
Control groups were left untreated. Cells in 96-well plates were
counted in trypan blue on days 4, 6, and 8. Cells in flasks were
centrifuged on Histopaque-1077, washed, counted, and used for
further studies. For protein analysis, 106 cells were solubilized in
RIPA lysis buffer containing 10% deoxycholate, 2% NP-40, 0.2%
SDS, and 10% glycerol, in Tris-buffered saline (TBS), pH 7.2.
Proteins were separated on 7.5% SDS-PAGE and transferred to
nitrocellulose (MCI, Westboro, MA). Filters were blockedin 0.5%
gelatin in TBS andthen incubated with murine monoclonal anti-
ABL antibody (the kind gift of Dr. R. Arlinghaus, MD Anderson
Medical Center, Houston, TX), murine monoclonal anti-c-MYC
antibody (Oncogene Science Inc., Uniondale, NJ), and murine
monoclonal anti-HSP 72/73 (Oncogene Science Inc.). Filters
were washed five times with 0.25% Tween, 0.25% NP-40 in
TBS buffer and blotted with anti-murine polyclonal antibody
linked to horseradish peroxidase (Amersham Corp., Arlington
Heights, IL). Proteins were detected using enhanced chemilumi-
nescence Western blotting detection system (Amersham Corp.)
For cell cycle analysis, cells (106) were fixed in 70% ethanol for 15
min at 4°C, washed, and incubated in 1 ml ofPBS plus 0.1% NP-
40 plus 1 N,g/ml of DNAse-free RNAse (Boehringer Mannheim
Co., Indianapolis, IN) for 10 min at room temperature. Propid-
iumiodide (5 1Lg/ml) was added, and cells were analyzed (EPICS
Profile analyzer; Coulter Corp., Hialeah, FL).
[S]ODNs Treatment ofBV173 Cells orHL60 Cells In Vivo.
￿
SCID
mice inoculated intravenously with 106 BV173 cells or 106 HL60
cells 7 d earlier were treated intravenously with [S]ODNs (0.2 ml
of RPMI 1640 medium, bolus injection) at 1 mg/d for 12 con-
secutive days. 1 d after the treatmentwas stopped, cells were col-
lected from various organs of the mice injected with BV173 cells,
and the presence of leukemia was analyzed by flow cytometry
(CD10+ cells), clonogenic assay (leukemia colony-forming cells),
and reverse transcriptase (RT)-PCR (detection of bcr-abl tran-
scripts) as previously described (19).
Quantitative RT-PCR (Qt/RT-PCR).
￿
Total RNA from 5 X
106 bone marrow cells of b2/a2 AS- and b2/a2 plus c-myc AS-
treated mice was extracted and adjusted to the same concentra-
tion, and equal amounts of [3-actin were detected in 1 p.l of each
sample by RT-PCR to confirmthesame quality ofisolated RNA.
The material was divided into five equal samples, and an increas-
ing amount (from 0 to 100 ng) of total RNA from K562 cells
(b3/a2 junction) was added to each sample as asource of compet-
itive RNA. RT-PCR performed using a 3' primer from ABL
exon 2 and a 5' primer from BCR exon 2 generated two cDNA
fragments, 257-bp b2/a2 and 332-bp b3/a2, during 25 cycles of
PCR amplification. Fragments were detected by Southern blot-
ting using as probe an internal oligomer corresponding to a seg-
ment of the c-ABL exon 2.
Tissue Distribution of Intact [S]ODNs.
￿
SCID mice were in-
jected (1 mg/d for 12 consecutive days) with b2/a2plus c-myc AS
[S]ODNs. 24 h after the last injection, DNA obtained from 106
cells ofvarious tissues was subjected to electrophoresis, and intra-
cellular [S]ODNs were detected by specific hybridization with
complementary oligoprobes as previously described (19). For de-
tection of intact [S]ODNs in BV173 cells infiltrating mouse tis-
sues, leukemic SCID mice were injected (1 mg/d for 12 consecu-
tive days) with bcr-abl, c-myc, or b2/a2 plus c-myc AS [S]ODNs.
24 h after the last injection, CD10+ BV173 were isolated by im-
munosorting from bone marrow and spleen cell suspensions. Af-
ter DNA isolation, intracellular [S]ODNs were detected as de-
scribed (19) .
Results
Effects of bcr-abl and/or c-myc AS [S]ODNs on BV173
Cells. In vitro, proliferation ofPhiladelphiaI-positive BV173
cells that carry the bcr exon 2-abl exon 2 (b2/a2) junction
was completely inhibited in the presence ofb2/a2 or c-myc
AS ODNs at a concentration of 10 N,g/ml each (Fig. 1 A),
whereas, in combination, the [S]ODNs inhibited prolifera-
tion at a two- and fourfold lower final concentration, i.e.,
concentrations at which the individual [S]ODNs were nearly
or completely ineffective (Fig. 1 A). S [S]ODNs were non-
inhibitory at any concentration tested. BV173 cell prolifer-
ation was equallyinhibited by a 15-mer c-mycAS [S]ODN
(5' AAC GTT GAG GGG CAT 3'). In contrast, a c-myc-
scrambled sequence (5' AAG CAT ACG GGG TGT 3')
including the G tetrad reported to exert nonspecific anti-
proliferative effects on epithelial cells (23) was completely
ineffective (not shown) . Partial inhibition of BV173 cell
proliferation using 5 N,g/ml of b2/a2 or c-myc AS [S]ODNs
was accompanied by a partial down-regulation of BCR-
ABL and c-MYC protein levels, respectively (Fig. 1 B) .
Incubation of the cells with higher concentrations of AS
[S]ODNs, causing complete inhibition of cellular prolifera-
tion, induced much stronger down-regulation of BCR-
ABL and c-MYC protein expression (19, 20). The com-
bined treatment with low concentrations of b2/a2 plus
c-myc AS [S]ODNs (2 .5 Vg/nil each) down-regulated both
BCR-ABL and c-MYC protein. Expression of MYC pro-
tein was also partially inhibited by b2/a2 AS [S]ODNs,
which might rest in the functional linkage between BCR-
ABL and c-myc, as suggested by studies indicating increased
c-myc expression in BCR-ABL-transfected cells (17) . Anal-
ysis ofcellular DNA content (cell cycle distribution) by flow
cytometry revealed that treatment with b2/a2 or c-myc AS
[S]ODNs as well as with a combination ofboth AS [S]ODNs
at concentrations affecting their proliferation led, after 48
and 72 h, to accumulation of cells in S phase of the cell cy-
cle, concomitant with a decrease in the proportion of G,
and GZ cells and with the appearance ofcells with fractional
DNA content (Fig. 1 C) . The cells with fractional DNA
content are typical ofcells dying by mode ofapoptosis (24).
The degraded, low-molecular weight DNA from apop-
totic cells is generally extracted before andduring the stain-
ing procedure; such cells, as well as the apoptotic bodies, stain
with much lower intensity with the DNA fluorochromes,
representing the "sub-Gl " cell population on the DNA fre-
quency histograms. The apoptotic mode of cell death was
confirmed by observation of cell morphology after differ-
ential staining of DNA and protein (Fig. 1 D) . The changes
characteristic of apoptosis, involving cell shrinkage, chro-
matin condensation, fragmentation of nuclei, hyperchro-
micity of chromatin, and shedding of apoptotic bodies,
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a combination ofboth AS [S]ODNs. After 48 and especially
after 72 h, there were numerous very late apoptotic cells in
these cultures, containing very little or almost no stainable
DNA (Fig. 1 D) . In all probability, these cells were repre-
sented on the DNA content frequency histograms by the
distinct peaks near the origin of the DNA content coordi-
nate, characteristic ofcells with minimal DNA content.
Effects of bcr-abl, c-myc, or bcr-abl plus c-myc AS [S]ODNs
on Leukemia Progression in SCID Mice. We assessed the an-
tileukemic effects ofbcr-abl and c-myc ODNs, alone and in
combination, in immunodeficient SCID mice (males 8-10
wk old, 20-22 g) injected intravenously with 106 BV173
cells, a regimen that produces a disease process reminiscent
of that in humans. 7 d later, mice were systemically injected
for 12 consecutive days with 1 mg/d per mouse ofb2/a2 S
plus c-myc S (6 d each, every other day), b2/a2 AS, c-myc
AS, or b2/a2 plus c-myc AS (6 d each, every other day).
Control mice were injected with diluent only. 4 wk after
leukemia implantation, peripheral blood, spleen (SPL), and
bone marrow (BMC) from one mouse per group were an-
alyzed to assess the disease process. Immunofluorescence as-
say (sensitivity 10-Z) did not detect CD10+ leukemic cells,
whereas colony assay (sensitivity 10-3) revealed several clo-
nogenic leukemia cells in BMC suspensions of control and
S [S]ODNs-treated mice, but none from cell suspensions of
mice treated with AS [S]ODNs either individually or in
combination (not shown). RT-PCR amplification of bcr-
abl transcripts present in the total RNA isolated from BMC
and SPL, followed by Southern blot hybridization, revealed
a relatively strong signal from amplification products ofRNA
isolated from control and S [S]ODN-treated mice, but only
a weak signal in RNA derived from tissue of mice treated
with individual ODNs, and a nearly undetectable signal in
RNA from the mouse treated with both b2/a2 and c-myc
AS [S]ODNs (not shown) . Equal amounts of [3-actin tran-
script were detected in RNA samples from each tissue.
8 wk afterleukemia cell injection, the disease process was
examined again in three mice (A, B, and C) from each group
by immunofluorescence, colony assay, and RT-PCR using
RNA ofvarious tissues. Immunofluorescence assay detected
CD10+ cells in PBL (only one mouse was positive), SPL,
and BMC of control and S [S]ODN-treated mice, but not
in the corresponding tissues of the mice treated with AS
ODNs (Table 1) . The more sensitive clonogenic assay re-
vealed several leukemic colonies in PBL and abundant col-
onies in SPL and BMC of control and S [S]ODN-treated
mice; in contrast, cell suspensions of c-myc or b2/a2 AS-
treated mice contained far fewer malignant colonogenic cells
(Table 1). Only one of the mice treated with both b2/a2
and c-myc AS ODNs contained detectable clonogenic leu-
kemic cells. Scoring of superficial liver metastases was con-
sistent with immunofluorescence and clonogenic assays (Ta-
ble 2) . Numerous metastatic nodules were visible on the
surface of livers from control and S-treated mice, several
were visible on the liver of mice treated with single AS,
and none were visible on the organs from mice treated
with both AS [S]ODNs. RT-PCR amplification ofbcr-abl
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Table 1.
￿
Presence of CD 10' and Leukemia Clonogenic Cells in
SCID Mice Injected with BV173 Cells and Treated u4th bcr-abl (b2/
a2) or/and c-myc(S]ODNs
Leukemic colonies/
CD10+ cells
￿
105 cells
Mice were inoculated intravenously with 106 BV173 cells and, 7 d
later, injected intravenously with S or AS [S]ODNs (1 mg per mouse
per day) for 12 consecutive days; in the combination group (b2/a2 plus
c-myc), [S]ODNs were injected every otherday. Control mice were in-
jected with diluent only. Leukemia growth in the mice was analyzed
on day 56 by assessing PBL, SPL, and BMC for CD10+ cells by immu-
nocytometry and for clonogenic growth in methylcellulose. Numbers
show individual results obtained from three mice (A, B, and C). NT,
not tested.
transcripts in RNA isolated from various tissues of control
and S [S]ODN-treated animals (three mice per group) re-
vealed bcr-abl transcripts in each ofthese tissues (Fig. 2 A).
bcr-abl transcripts were also detected in all tissues except
the brain ofmice treated with single AS [S]ODNs, but the
signal was much weaker than that observed with control
and S [S]ODN-treated mouse tissues. Even weaker signals
were detected in the RNA isolated from all the organs ex-
cept the brain of mice injected with b2/a2 plus c-myc AS
[S]ODNs, suggesting that the leukemic cell load in mice
treated with [S]ODNs in combination was reduced as com-
paredwith that ofmice treated with individual ODNs. The
detection of equal amounts of (3-actin in each group of or-
gans indicated the integrity and equal loading of the ampli-
fied products.
To confirm that the differences in the intensity of the
bcr-abl bands corresponding to tissues of single versus com-
bined AS [S]ODN-treated mice reflected the difference in
amounts of bcr-abl transcript in the tissues, we performed
Qt/RT-PCR using the same amount ofRNA isolated from
Treatment mice PBL SPL BMC PBL SPL BMC
Control A 1 .4 6.1 24.9 19 559 2,519
B 0 4.9 11 .6 7 252 1,579
C 0 5 .0 7 .4 2 258 1,166
b2/a2 S A NT 6.3 38.5 NT 588 3,005
+ c-mycS B 0 6.5 10.4 4 239 1,389
C 0 4.2 7.0 0 194 1,214
b2/a2 AS A 0 0 0 0 5 4
B 0 0 0 0 5 9
C 0 0 0 0 9 19
c-mycAS A 0 0 0 0 13 20
B 0 0 0 0 8 37
C 0 0 0 0 4 22
b2/a2 AS A 0 0 0 0 0 0
+ c-mycAS B 0 0 0 0 0 1
C 0 0 0 0 0 025.0
20 .0
15.0
10.0
so
A
10 ua/m l
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BMC of b2/a2 and b2/a2 plus c-myc AS [S]ODN-treated
mice, in the presence of increasing amounts ofRNA from
K562 cells (b3/a2) as a source of competitive bcr-abl RNA,
and using optimal concentrations of primers . Integrity of
the isolated RNA was confirmed by RT-PCR, which de-
tected similar amounts of P-actin transcript . Qt/RT-PCR
revealed competitive blocking of the b2/a2 transcript (from
BV173 cells present in the tissue) at lower K562 RNA con-
centrations when BMC were isolated from mice injected
GO/Gl" 39,9%
5151
250
20.0
15 .0
100
5.0
0.0
C
￿
24 h
￿
48 h
￿
72 h
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Figure 1 . Effects of b2/a2 and c-myc
ODNs on BV173 cells . (A) Proliferation as-
say. Cells were incubated at the indicated fi-
nal concentrations of b2/a2 and/or c-myc
[S]ODNs, or were left untreated (control) .
(O), control ; (A), b2/a2 and c-myc S ; (O),
b2/a2 AS ; (" ), c-myc AS; ("), b2/a2 AS
plus c-myc AS . Live cells were counted at
the indicated days by trypan blue exclusion
test. (B) Protein levels . Total cellular pro-
teins were isolated from BV173 cells after
72 h of incubation without [S]ODNs (con-
trol) or with 5 jig/nil of indicated
[S]ODNs, and were analyzed by SDS-
PAGE and Western blotting for the expres-
sion ofthe indicated proteins. (C) Cell cycle
analysis . After incubation for 24, 48, and 72 h,
in the presence of the indicated concentra-
tions ofAS [S]ODNs (a, 5 jig/nil b2/a2 ; b,
5 N.g/ml c-myc ; c, 2 .5 jig/ml b2/a2 ; d, 5 wg/rrfl b2/a2 plus c-myc), DNA content was determined by flow cytometry . (D) UV fluorescence photographs
of untreated and [S]ODN-treated BV173 cells stained with the DNA fluorochrome 4',6' diamedino-2-phenylindole and protein fluorochrome sulfo-
rhodamine 101 . (a) Control, untreated cells ; (b) cells treated with b2/a2 AS [S]ODNs (5 jig/ml) for 48 h . Note the typical apoptotic cell with fragmented
nucleus and highly condensed chromatin, uniformly and strongly stainable with 4',6' diamedino-2-phenylindole . (c) Cells treated with a combination of
b2/a2 and c-myc AS [S]ODN (2 .5 lag/rrml each) for 48 h . Note one early apoptotic cell with typical chromatin condensation and nuclear fragmentation
and four cells in very late stage of apoptosis, which shrunk and lost nearly allDNA. (d) Cells treated as in c, but for 72 h.
GO/Gl" 3951
5= 9J.1%
G2/* 10,f%
with both AS ODNs as compared with those receiving
only one antisense [S]ODN (Fig. 2 B), indicating the lower
amounts of bcr-abl transcripts in BMC RNA from the
combined versus single AS ODN-treated mice . These re-
sults are consistent with those obtained by nonquantitative
RT-PCR, immunofluorescence, and clonogenic assays,
and by assessment ofliver metastases .
Analysis of two other b2/a2 plus c-myc AS [S]ODN-
treated mice 20 wk after leukemia implantation, when all
0 250
GWl " 352%
S . RA
G2jhk 1051
0 aFigure 1.
￿
(Continued)
mice treated with individual [S]ODNs were dead, revealed
different degrees of disease process as reflected by the tu-
mor load of the two mice (Table 3). Analysis of leukemia
progression in a separate set of experiments involving five
mice per group confirmed the advantage of targeting coop-
erating versus individual oncogenes as a therapeutic strategy
for tumor treatment (not shown) .
Such differences among the groups of mice were re-
flected in their mortality rates (Fig. 3 A); all nine control
and nine S [S]ODN-treated mice died with diffuse leuke-
mia, as confirmed by necropsy, 7-10 wk after intravenous
injection of 106 BV173 leukemia cells (mean survival time
7.7 ± 0.8 and 8.3 ± 0.5 wk, respectively). In contrast, the
nine b2/a2 AS [S]ODN- and nine c-myc AS [S]ODN-
treated mice died after 14-18 and 14-19 wk; of leukemia
growth, respectively (mean survival time 14.7 ± 0.8 and
14.8 ± 0.9 wk, respectively; P <0.001 compared with
control or S-treated groups) . Nine mice treated with both
AS [S]ODNs survived significantly longer (mean survival
time 30.8 ± 10.9 wk; P <0.001 compared with mice
treated with either AS ODNs).
In contrast, the combination ofb2/a2 and c-myc AS ODNs
did not exert synergistic antitumor effect in SCID mice
bearing Ph'-negative HL60 leukemic cells (Fig. 3 B) . All
1649
￿
Skorski et al_
eight control mice died with diffuse leukemia, as confirmed
by necropsy, 7-8 wk after injection of 106 HL60 cells (mean
survival time 7.0 ± 0.5 wk) . The group treated with b2/a2
AS ODNs (1 mg/d for 12 consecutive days) died after 7-8
wk. The group treated with c-myc AS ODNs (1 mg/day for
12 consecutive days) died after 11-13 wk, and the group
treated with b2/a2 plus c-myc AS ODNs (1 mg/d, 6 d each,
every other day) died after 10-11 wk of leukemia. The
Table 2.
￿
Superficial Metastases in the LiverofSCID Mice Injected
with BV173 Cells and Treated with b2/a2, c-myc, or b2/a2 -+ c-myc
AS or S (SJODNs
Treatment groups
￿
Number ofmetastases
Control
￿
89, 54, 88
b2/a2 + c-myc S
￿
156, 107, 61
b2/a2 AS
￿
12, 10,8
c-myc AS
￿
15, 15, 4
b2/a2 AS + c-myc AS
￿
0, 0, 0
Mice were treated as described in the Table 1 legend. Numbers indi-
cate visible liver metastases in three mice per group.Figure 2 .
￿
(A) Detection ofbcr-abl transcripts byRT-PCR inRNA from tissues of [S10DNs treated (b2/a2 plus c-myc S, b2/a2 AS, c-myc AS, or b2/
a2 plus c-myc AS) or untreated (control) leukemic SCID mice . bcr-abl and [3-actin transcripts were separately detected by RT-PCR (13) using total
RNA from 5 X 105 cells for each tissue sample, 56 d after leukemia implantation . Blots were exposed after 24 h (bcr-abl) and 2 h ([3-actin) . The blot is
representative of three different experiments using three mice per group . (B) Comparison of the amount ofbcr-abl transcripts by Qt/RT-PCR (16) in
BMC ofb2/a2 AS- and b2/a2 plus c-myc AS-treated mice . Various amounts of totalRNA isolated from K562 (b3/a2 junction) cells (lane 1, no RNA ;
lane 2, 0 .1 ng; lane 3, 1 ng; lane 4, 10 ng ; lane 5, 100 ng) were added as a source of competitive bcr-abl-containing RNA to the same amount oftotal
RNA isolated from 106BMC obtained from b2/a2 AS- or b2/a2 AS plus c-myc AS-treated mice . Southern blot analysis ofRT-PCR amplification prod-
ucts detects the b2/a2 fragment from BV173 RNA contaminating mouse BMC (lower band) RNA, and the b3/a2 fragment from the K562 RNA (upper
band) added as competitor . The blot is representative of two different experiments .
mean survival times were 7.3 ± 0.8, 11 .6 ± 0.7, and 10.4
± 0.5 wk, respectively. Thus, the combination of bcr-abl
(b2/a2) and c-mycAS ODNs exerted specific antitumor ef-
fects and was much more effective than individual AS
ODNs in treating mice bearing Ph' leukemia .
Detection ofbcr-abl and c-mycAS[S]ODNs in Mouse Tissues
and Leukemic Cells . The leukemia-suppressive effects ofAS
[S]ODNs correlated well with their detection in all organs
examined except the brain, although blot hybridization of
tissue DNA isolated 1 d after the last injection showed the
highest ODN concentrations in the liver and spleen (Fig . 4
A) . [S]ODNs were still detectable in these organs 7 d after
the last injection (not shown) . Intact b2/a2 and c-myc AS
[S]ODNs were simultaneously detected in vivo in leuke-
Leukemic colonies
per 105 cells
Mice PBL SPL BMC PBL SPL
D 0 2 236 - +
E 53 283 2387 + +++
mic cells infiltratingBMC and SPL ofSCID mice 1 d after
completion ofthe injection protocol, by immunosorting of
CD10+ cells and Southern blot hybridization of the iso-
latedDNA with oligomer probes complementary to either
c-myc or bcr-abl AS [S]ODNs (Fig . 4 B) .
Discussion
The oncogene-targeted approach for the treatment of
neoplastic disorders offers the possibility ofselectively block-
ing the function of genes responsible for disease, as com-
pared with the less selective antitumor effects of conven-
tional chemotherapy and radiotherapy . Initial in vivo data
in animal models suggest that targeting a single oncogene
Table 3 .
￿
Leukemia Growth in SCID Mice 20 wk after Injection of 106 BV173 Cells and Treatment with b2/a2 Plus c-mycAS [S]ODNs
bcr-abl messenger RNA levels
Liver
BMC LIV LNG BRN metastases
Two mice (D and E) were analyzed . The abbreviations are the same as in Fig. 2 . Leukemic colonies were counted after a 9-d culture in methylcel-
lulose. Intensity ofthe RT-PCR band was evaluated after blotting with a junction-specific -y-32P-labeled probe and exposing the filters for different
times : (-), not detectable after 7-d exposure ; (+), visible after 7-d exposure; (++), visible after 24-h exposure ; (+++), visible after 1-h exposure .
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Figure 3 .
￿
Survival of leukemic SCID mice treated with b2/a2 and/or
c-myc [S]ODNs. Mice injected with 106 BV173 cells (A) or 106 HL60
cells (B) were treated intravenously 7 d later with 1 mg/mouse per day of
b2/a2 S plus c-myc S (" ) ; b2/A2 AS (O) ; c-myc AS (A), or b2/a2 AS plus
c-myc AS (" ) [S]ODNs for 12 consecutive days . Control (O) mice re-
ceived diluent only .
by AS [S]ODNs is associated with temporary suppression
of tumor growth (19, 25-28) . Because tumor formation is a
multistep process involving altered function of several on-
cogenes, the success of oncogene-targeted therapy is likely
to depend on the ability to target more than one gene crit-
ical for the maintenance of the tumor phenotype . In our
studies involving multiple oncogenes targeting in CML cells,
in addition to bcr-abl, we targeted c-myc because this gene
appears to be necessary for the transforming ability of bcr-
abl (14-18), perhaps as one of the nuclear end points of
BCR-ABL activity . Both bcr-abl and c-myc AS [S]ODNs
can inhibit in vitro proliferation ofPhiladelphia' cells while
sparing, at the doses used, that of erythromyeloid hemato-
poietic progenitor cells (20-22, 29) . In combination, these
[S]ODNs exerted a specific synergistic antiproliferative ef-
fect on BV173 cells at concentrations at which individual
AS [S]ODNs were only partially effective or were completely
ineffective .
The flow cytometric data indicate that exposure of cells
to b2/a2 or c-mycAS [S]ODNs or to a combination ofthese
[S]ODNs, while not precluding cell entrance into S phase,
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Figure 4 .
￿
Detection of intact b2/a2 and c-myr [S]ODNs in mouse tis-
sues (A) and in the CD10+ BV173 leukemia cells infiltrating bone mar-
row and spleen (B) by Southern blot hybridization . Intact [S]ODNs in
mouse tissues were detected by specific hybridization with complemen-
tary oligoprobes as described (19) . Intracellular detection of bcr-abl and
c-myc [S]ODNs in BV173 cells infiltrating marrow and spleen was ana-
lyzed in two separate mice (lanes bcr/abl + c-myc) . A single mouse was
used for intracellular detection ofeither bcr-abl or c-myc [S]ODN . Stan-
dard 26-mer AS [S]ODNs were run as controls in Fig. 4 B .
does prevent cell progression through S . While the S phase
function of bcr-abl has not been previously reported, the S
phase arrest in c-myc AS [S]ODN-treated cells is in agree-
ment with the reported ability of ectopically expressed c-myc
gene to rescue S phase arrest of the hematopoietic IL-3-
dependent BAF-1303 cell line stimulated via the epidermal
growth factor receptor (30) . The interference with S phase
progression ofBV173 cells treated with b2/a2 and/or c-myc
AS [S]ODNs may provide a signal triggering apoptosis . This
mechanism is analogous to the death of prostate epithelial
cells after testosterone depletion, when the cells enter the
"defective" cell cycle and die by apoptosis while progress-
ing through S (31) .
Leukemic SCID mice treated with both bcr-abl and c-myc
AS [S]ODNs survived much longer than those injected with
the same dose of single AS [S]ODNs . Although the reason
for this effect remains unclear, it seems likely thatAS [S]ODNs
reach a plateau in their ability to down-regulate gene expres-
sion in vivo that is not sufficient to completely block cell pro-
liferation . Targeting of a second oncogene involved in the
disease process may arrest the growth of cells that escaped the
inhibitory effect associated with individual gene targeting. Al-
ternatively, the down-regulation of gene expression by sin-
gle AS [S]ODNs at the relatively low concentrations reached
in vivo (19) might be insufficient to inhibit cell prolifera-
tion, wheras "partial" inhibition of two cooperating onco-
genes might induce a more permanent block in the ability
to proliferate . Our in vitro experiments using different con-
centrations ofAS [S]ODNs separately and in combination
do not exclude either possibility . In additional experiments,
we found that the simultaneous down-regulation ofBCR-
ABL and c-myb, but not BCR-ABL andDNA polymerase
cx, exerted synergistic antitumor effects (data not shown) . This
suggests that simultaneous inhibition of the expression of
BCR/ABL and of other genes involved in proliferation of
CML cells (i.e ., DNA polymerase a) does not necessarily ex-
ert synergistic antitumor effects, and raises the possibility that
a functional relationship between BCR-ABL and other
genes is required for these effects . The enhanced antileuke-
mic effect observed with ODNs in combination was not
associated with nonspecific toxicity on normal cells . Ourprevious studies showed that bcr-abl [S]ODNs used at
doses similar to those used here were nontoxic to mice har-
boring leukemic cells (19) . In similar experiments, control
mice injected with murine c-myc AS [S]ODNs revealed no
major toxicity-associated morphological changes in the or-
gans examined and no decrement in the proliferative capac-
ity of BMC as indicated by clonogenic assays (not shown),
suggesting that bcr-abl and c-myc AS [S]ODNs have favor-
able pharmacological properties in vivo. Systemic treatment
with [S]ODNs was associated, however, with moderate
hepatosplenomegaly, a not uncommon observation after in-
jection of [S]ODNs (19, 28, 32).
To exclude the possibility that the antileukemia effects
were due to the nonspecific activity of [S]ODNs (33), sev-
eral control experiments were performed. BV173 cells are
not sensitive to b2/a2 or c-mycS [S]ODNs as well as to 6-bp
mismatched AS [S]ODNs (19, 20) . Because the c-myc AS
[S]ODN contains the G tetrad, a sequence shown to exert
antiproliferative effects independent of an AS mechanism
on cells growing in monolayer (23), we have used a c-myc-
scrambled [S]ODN preserving the G tetrad and found that
it is nontoxic to BV173, HL60, and K562 cells (not
shown) . The recent observation that closely spaced repeats
of the consensus sequence GGC are critical for inhibition
of BCR-ABL tyrosine kinase autophosphorylation (34),
which is crucial for its transformation ability (35), raises the
possibility that AS [S]ODNs may act in an aptameric fash-
ion. However, the [S]ODNs we had used do not contain
closely spaced GGC sequences . Moreover, treatment of
BV173 cells with b2/a2 AS [S]ODNs did not decrease the
phosphorylation of p210 BCR-ABL and other proteins
during the initial 48 h of incubation, and then the decrease
in phosphorylation was proportional to the decrement in
the p2 I OBCRIABL protein levels (not shown) . These two find-
ings strongly argue against a primary aptameric mechanism
as an explanation of the antileukemia effects seen with the
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